Skip to main content
[Preprint]. 2023 Jan 20:2023.01.20.23284646. [Version 1] doi: 10.1101/2023.01.20.23284646

Table 1.

Summary of characteristics of seven cases with rare pathogenic PAM variants

ID Diagnosis Gender Pathogenic PAM variant(s) Ethnicity Age at disease onset (years) Age at PA diagnosis (years) Tumor size (mm) Treatment Other clinical diagnoses

II-2* GH excess (gigantism) M c.2108G>A (p.Arg703Gln) Caucasian <10 35–40 4 PegV hypogonadism, adrenal nodules, pleural masses, severe osteopenia, muscular atrophy, diverticulosis
II-3* GH excess (gigantism) M c.2108G>A (p.Arg703Gln) Caucasian <10 35–40 5x6 TSS, SSA, PV hypogonadism, pancreatic and colon adenocarcinoma
III-3* GH excess (gigantism) M c.2108G>A (p.Arg703Gln) Caucasian 1–5 1–5 n.a. SSA, PegV hypotonia
NIH26 pediatric CD F c.2332-2A>T (p.His778fs) Caucasian 10–15 10–15 3 TSS scleroderma
NIH36 pediatric CD F c.-133T>C African-American 10–15 10–15 10 TSS (×3) no
Belgium128 GH excess (gigantism) M c.2276T>C (p.Phe759Ser) Latino 15–20 20’s Macro TSS, SRL none
Belgium197 GH excess (acromegaly) M c.1654G>A (p.Gly552Arg), c.1688A>G (p.Asp563Gly) Caucasian 40’s 40’s 40 TSS, SRL, RTx none

F, female; M, male; n.a., not applicable; PA, pituitary adenoma; PegV, pegvisomant; RTx, radiotherapy; SRL, somatostatin receptor ligand; TSS, transsphenoidal surgery.

*

Member of the index FIPA kindred.